Buffer

Offices: how bad will the property crunch be?

Retrieved on: 
Sunday, August 13, 2023

This is compounded by the longstanding anxieties around retail due to the move from bricks and mortar to more online shopping.

Key Points: 
  • This is compounded by the longstanding anxieties around retail due to the move from bricks and mortar to more online shopping.
  • Charlie Munger, Warren Buffett’s right-hand man, has warned of a major pullback in lending to commercial property.
  • He argues that American banks are full of bad loans associated with previously lucrative assets.

The changing market

    • Factory demand is up by nearly a third year on year from businesses “nearshoring” in response to heightened geopolitical tensions.
    • Across the board, there’s always some churn in commercial vacancies as the market ebbs and flows.
    • Underlying these concerns are disruptions in the market.
    • Ever since it became easier to invest in commercial property in the 1960s, the market was landlord-led.

Where we’re heading

    • The same goes for those with poor sustainability ratings, long leases and few nearby shops and childcare amenities.
    • Single-use locations like Canary Wharf and office parks dominated by traditional grid-like designs are at most risk because they are least appealing and don’t lend themselves to adaptation.
    • Buildings like these are becoming stranded assets, not just because of their physical attributes but also because no one really knows what they are worth at the moment.
    • If lenders allow some leeway during this transition rather than foreclosing aggressively, hopefully the worst pain can be avoided.

Offices: how bad will the coming property crunch be?

Retrieved on: 
Friday, August 11, 2023

This is compounded by the longstanding anxieties around retail due to the move from bricks and mortar to more online shopping.

Key Points: 
  • This is compounded by the longstanding anxieties around retail due to the move from bricks and mortar to more online shopping.
  • Charlie Munger, Warren Buffett’s right-hand man, has warned of a major pullback in lending to commercial property.
  • He argues that American banks are full of bad loans associated with previously lucrative assets.

The changing market

    • Factory demand is up by nearly a third year on year from businesses “nearshoring” in response to heightened geopolitical tensions.
    • Across the board, there’s always some churn in commercial vacancies as the market ebbs and flows.
    • Underlying these concerns are disruptions in the market.
    • Ever since it became easier to invest in commercial property in the 1960s, the market was landlord-led.

Where we’re heading

    • The same goes for those with poor sustainability ratings, long leases and few nearby shops and childcare amenities.
    • Single-use locations like Canary Wharf and office parks dominated by traditional grid-like designs are at most risk because they are least appealing and don’t lend themselves to adaptation.
    • Buildings like these are becoming stranded assets, not just because of their physical attributes but also because no one really knows what they are worth at the moment.
    • If lenders allow some leeway during this transition rather than foreclosing aggressively, hopefully the worst pain can be avoided.

AM Best Removes From Under Review With Negative Implications and Affirms Credit Ratings of Ghana Reinsurance PLC

Retrieved on: 
Thursday, August 10, 2023

AM Best has removed from under review with negative implications and affirmed the Financial Strength Rating of B- (Fair) and the Long-Term Issuer Credit Rating of “bb-” (Fair) of Ghana Reinsurance PLC (Ghana Re) (Ghana).

Key Points: 
  • AM Best has removed from under review with negative implications and affirmed the Financial Strength Rating of B- (Fair) and the Long-Term Issuer Credit Rating of “bb-” (Fair) of Ghana Reinsurance PLC (Ghana Re) (Ghana).
  • The outlook assigned to these Credit Ratings (ratings) is negative.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

Global Banks Progressing towards Go-live on the Finteum Platform

Retrieved on: 
Tuesday, August 8, 2023

The Finteum Platform is an execution venue that brings intraday funding capabilities to the global interbank market.

Key Points: 
  • The Finteum Platform is an execution venue that brings intraday funding capabilities to the global interbank market.
  • The banks progressing with the integration work and planning to go live soon include UBS and NatWest.
  • Intraday FX swaps and intraday repo are recognised to be an increasingly important part of liquidity management strategies at global banks.
  • Finteum is building out the second wave of banks that will go live on the platform in 2024 and will start benefiting from intraday markets.

Teknova and Sartorius BIA Separations Share Data Demonstrating Reliable and Scalable Approach for the Enhancement of AAV Full Capsid Enrichment with an Optimized AEX Platform

Retrieved on: 
Thursday, July 20, 2023

Teknova presented the findings from the companies’ first collaboration earlier this week during a presentation entitled, “Enhancing AAV Full Capsid Enrichment with an Optimized AEX Platform: A Case Study."

Key Points: 
  • Teknova presented the findings from the companies’ first collaboration earlier this week during a presentation entitled, “Enhancing AAV Full Capsid Enrichment with an Optimized AEX Platform: A Case Study."
  • After identifying capsid enrichment as a critical pain point in the AAV gene therapy workflow, Teknova and Sartorius BIA Separations began working together to address the challenges gene therapy developers face.
  • Teknova and Sartorius BIA Separations continue to develop data demonstrating improvements in AAV purification, and plan to share additional findings in the future.
  • For information about Sartorius BIA Separations CIMmultus QA monoliths or to purchase one online, visit sartorius.com .

Toews Agility Shares™ Managed Risk ETF Recognized as Top Rated among Morningstar’s Options Trading ETFs Over 3-Year Period

Retrieved on: 
Friday, July 14, 2023

Toews Agility Shares™ Managed Risk ETF (NYSE: MRSK), rated 5 stars by Morningstar out of 90 ETFs in the Options Trading Category* for the three year period ending June 30, 2023, seeks constant US equity exposure employing an options strategy to manage risk.

Key Points: 
  • Toews Agility Shares™ Managed Risk ETF (NYSE: MRSK), rated 5 stars by Morningstar out of 90 ETFs in the Options Trading Category* for the three year period ending June 30, 2023, seeks constant US equity exposure employing an options strategy to manage risk.
  • This investment strategy seeks to provide a constant hedge for market downside without limiting market exposure to equity rallies.
  • This strategy has historically been able to navigate the dichotomy of stocks’ upward momentum and the longer term heightened risk of markets, spurred by prolonged inflation and growing global debt.
  • “Many hedged products on the market offer buffers that place limits or caps on gains and only account for a specific percentage of market decline.

Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development

Retrieved on: 
Tuesday, July 11, 2023

“After we introduced our first proprietary gene therapy product a few months ago – the AAV-Tek AEX Buffer Screening Kit for AAV2 – customers encouraged us to create additional solutions to better support AAV gene therapy developers,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer.

Key Points: 
  • “After we introduced our first proprietary gene therapy product a few months ago – the AAV-Tek AEX Buffer Screening Kit for AAV2 – customers encouraged us to create additional solutions to better support AAV gene therapy developers,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer.
  • “In a few short months, our talented team has delivered the AEX Buffer Screening Kit for AAV8, specifically designed to help gene therapy developers save months in process development time.
  • We’re also making available more than 20 additional reagents we’ve identified as key solutions to support the entire gene therapy workflow.
  • For more information about the suite of AAV gene therapy workflow solutions or to purchase them online, visit www.teknova.com/aav-workflow .

Global Single-use Bioreactors Market 2023 to 2030: Increasing Adoption of SUBs Among Small Companies and Startups Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 7, 2023

The global single-use bioreactors market size is expected to reach USD 12.06 billion by 2030, registering a CAGR of 17.19% from 2023 to 2030.

Key Points: 
  • The global single-use bioreactors market size is expected to reach USD 12.06 billion by 2030, registering a CAGR of 17.19% from 2023 to 2030.
  • Owing to the rising demand for biopharmaceuticals, coupled with increasing investments in single-use technologies, the market for single-use bioreactors is expected to witness significant growth throughout the forecast period.
  • The segment is being driven by the increasing usage of single-use bioreactors for mammalian cell culture in several research studies.
  • Factors such as rising investments and funding initiatives among Asian companies are expected to drive the market in the region.

Buffer Preparation Market Report 2023: Industry Trends and Global Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 5, 2023

The global buffer preparation systems market is anticipated to grow at a CAGR of around 10%, till 2035.

Key Points: 
  • The global buffer preparation systems market is anticipated to grow at a CAGR of around 10%, till 2035.
  • To overcome the challenges associated with conventional buffer preparation / buffer manufacturing processes, pharmaceutical players are either installing novel buffer preparation systems in their manufacturing facilities or outsourcing buffer manufacturing needs to third party service providers.
  • Presently, close to 45 buffer preparation / manufacturing systems are available in the market for buffer production.
  • In addition, the need for automated buffer preparation systems is expected to drive the buffer manufacturing market size during the forecast period.